This finding questions the clinical conclusion of the genomic variants found in plasma, since the increased survival observed in ERBB2 altered cases might be due to effective targeting of ERBB2 altered tumor cells by therapy to result in detection of these genomic variants in the plasma [48]. This evidence concerns the gene ERBB2 and neoplasm.